ArticleTargeted oncology2023

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.

Danilo De Novellis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.